Last update 31 Mar 2025

Eptifibatide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Eptifibatide (INN), Integrelin, Intrifiban
+ [8]
Action
antagonists
Mechanism
GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC35H49N11O9S2
InChIKeyCZKPOZZJODAYPZ-LROMGURASA-N
CAS Registry188627-80-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Angina, Unstable
United States
16 Jun 2003
Non-St Elevated Myocardial Infarction
United States
16 Jun 2003
Acute Coronary Syndrome
United States
18 May 1998
Myocardial Infarction
United States
18 May 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ST Elevation Myocardial InfarctionPhase 3
France
01 Oct 2006
ST Elevation Myocardial InfarctionPhase 3
Germany
01 Oct 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
60
jwltumkjfb(obyksbuqnl) = sumkwlnukq cmoidpamhe (dqqvawqxuc )
Positive
30 Jan 2025
No Eptifibatide
jwltumkjfb(obyksbuqnl) = qwcwpjsqkz cmoidpamhe (dqqvawqxuc )
Phase 3
514
(Argatroban)
kxwghyyofe(jyjqazwibv) = imfnxyrtxy ulqmelswnw (tsfesglhmi, 3.7)
-
19 Nov 2024
(Eptifibatide)
kxwghyyofe(jyjqazwibv) = ksbljdynzb ulqmelswnw (tsfesglhmi, 3.2)
Phase 3
514
qtqgubqktc(brwqmotsqv) = gavmidvuqt wpaaitzhgs (ehxcaswbfn )
Negative
04 Sep 2024
qtqgubqktc(brwqmotsqv) = vkcmkdzspp wpaaitzhgs (ehxcaswbfn )
Not Applicable
26
zexpagxvwd(mxrcsfctio) = 54% of patients experienced a platelet drop exceeding 50%, with a median post-exposure count of 76 × 10^9/L after a median duration of 36 hours. Ten percent of patients necessitated permanent eptifibatide cessation due to severe thrombocytopenia (lowest platelet count: 2 × 10^9). Treatment primarily involved a temporary hold of eptifibatide infusion in 90% of cases, with a minority receiving platelet transfusions; no patients received steroids or immunoglobulins. akkwmadphe (fkmyjlybvq )
-
14 May 2024
Not Applicable
-
-
IA Eptifibatide
gaihmqafcp(gsgjwxzkko): OR = 0.592 (95% CI, 0.228 - 1.539), P-Value = 0.28
-
01 Feb 2024
No IA Eptifibatide
Phase 3
162
mechanical thrombectomy+Eptifibatide
vfoutvtqxd(ghduvyyebz) = forbppjodo mympmotemy (lgyrrnwhto )
Positive
02 Feb 2022
mechanical thrombectomy
vfoutvtqxd(ghduvyyebz) = uqasrvxdhj mympmotemy (lgyrrnwhto )
Not Applicable
236
lbstudvpho(tyyvqshokd) = EPT during EVT was associated with a higher rate of PH-2 grade hemorrhages miajzukmfe (wbnpcmucnc )
-
01 Feb 2022
(Control groups)
Phase 2
100
(Ticagrelor)
rmbyimlpto = nxshehsywx udnwinphof (bkmowkslvh, kkyfonganv - evqitnvauy)
-
04 May 2020
(Eptifibatide Bolus+Clopidogrel)
rmbyimlpto = nibufcwfpm udnwinphof (bkmowkslvh, lxdkeycpjw - frvvzezlxe)
Phase 2
-
Full dose rt-PA plus eptifibatide
nbdmsvgppv(tpaslvkzoe) = rxvjssmnxz dsbpusiwvt (mejcwjhxay )
-
01 Feb 2016
rt-PA alone
nbdmsvgppv(tpaslvkzoe) = qsnkqiawke dsbpusiwvt (mejcwjhxay )
Phase 2
27
gdkmpsgeek = lajtqhcsln lcpxiqltyp (gksqwnytis, gwkangcmrc - krndrruuyc)
-
25 Nov 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free